Morning Buzz: Genocea Biosciences (NASDAQ:GNCA), Celldex Therapeutics (NASDAQ:CLDX), Ecopetrol SA (NYSE:EC), CorEnergy Infrastructure Trust, (NYSE:CORR), JA Solar Holdings (NASDAQ:JASO)

On Monday shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) closed at $10.22. Needham analyst Alan Carr reiterated a Buy rating on Genocea Biosciences (NASDAQ:GNCA) and set a price target of $22. The company’s shares opened today at $9.58.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) in last trading activity moved up 1.74% to close at $26.26. Company weekly performance is 2.30% while its quarterly performance stands at 22.48%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is -19.99% away from its 52 week high. Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced on 13 May, that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

On last trading day Ecopetrol SA (NYSE:EC) fell -2.70% to close at $15.87. Its volatility for the week is 3.78% while volatility for the month is 3.20%. EC’s sales growth for past 5 years was 18.50% and its EPS growth for past 5 years was 5.30%. Ecopetrol SA (NYSE:EC) monthly performance is -3.88%. On 14 May, Ecopetrol SA (NYSE:EC) said first-quarter profit fell 91 percent from a year earlier as the slump in oil prices weighed on the company. Net income for the group dropped to 355.9 billion pesos ($149 million), from 4.06 trillion pesos a year earlier, Bogota-based Ecopetrol said Tuesday in a statement after markets closed. That missed the expectation for profit excluding one-time items of 467.5 billion pesos, the average of three analysts’ estimates compiled by Bloomberg.

CorEnergy Infrastructure Trust, (NYSE:CORR) has 0.30% insider ownership while its institutional ownership stands at 51.60%. In last trading activity company’s stock closed at $6.78. CorEnergy Infrastructure Trust (NYSE:CORR) will begin trading ex-dividend on May 13, 2015. A cash dividend payment of $0.135 per share is scheduled to be paid on May 29, 2015.

On Monday shares of JA Solar Holdings Co., Ltd. (NASDAQ:JASO) closed at $9.50. Company’s sales growth for last 5 years was 24.50% and EPS growth for next 5 years is recorded as 22.00%. JA Solar Holdings Co., Ltd. (NASDAQ:JASO) said Monday that its first-quarter profit more than halved, as cell shipments plunged and shipments in China and the Americas declined.

Eye Catching Stocks: Dermira (NASDAQ:DERM), Molycorp (NYSE:MCP), Celldex Therapeutics (NASDAQ:CLDX), Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), First Bank (NASDAQ:FRBA)

On Wednesday shares of Dermira, Inc. (NASDAQ:DERM) closed at $14.67. Dermira Inc (NASDAQ:DERM) was upgraded by Zacksfrom a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Molycorp, Inc. (NYSE:MCP) in last trading activity moved down -16.25% to close at $0.67. Company weekly performance is -23.86% while its quarterly performance stands at -6.94%. Molycorp, Inc. (NYSE:MCP) is -85.81% away from its 52 week high. Molycorp Inc. (NYSE:MCP) is considering a proposal from senior creditors that would swap at least some of their bonds for equity as the rare-earths producer struggles to manage $1.6 billion of debt, according to two people with knowledge of the matter. Houlihan Lokey and Kramer Levin Naftalis & Frankel, which are advising holders of Molycorp’s $650 million of 10 percent first-lien secured notes maturing in June 2020, submitted the plan in late April and signed non-disclosure agreements, said the people, who asked not to be named because the matter is private.

On last trading day Celldex Therapeutics, Inc. (NASDAQ:CLDX) increased 1.19% to close at $24.60. Its volatility for the week is 5.20% while volatility for the month is 6.17%. CLDX’s sales growth for past 5 years was -25.00% and its EPS growth for past 5 years was 6.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) monthly performance is -9.53%. On April 29, Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported a loss of 33 cents in the first quarter of 2015, narrower than the Zacks Consensus Estimate of a loss of 36 cents per share and in-line with the year-ago loss. First quarter 2015 revenues increased 16.8% to $0.5 million, but missed the Zacks Consensus Estimate of $0.7 million.

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) has 41.59% insider ownership while its institutional ownership stands at 75.30%. In last trading activity company’s stock closed at $6.76. Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) has completed patient enrolment in the Phase II KINSHIP trial of its lead drug candidate, AQX-1125, to treat atopic dermatitis. AQX-1125 is a small molecule activator of SHIP1 suitable for oral, once daily dosing and it has been evaluated in multiple preclinical studies and clinical trials.

On last trading day First Bank (NASDAQ:FRBA) remains unchanged to close at $6.20. Its volatility for the week is 1.51% while volatility for the month is 1.45%. First Bank (NASDAQ:FRBA) monthly performance is 2.65%. On May 4, First Bank (NASDAQ:FRBA) announced first quarter 2015 results. Net income for the quarter was $1.7 million or $0.18 per diluted share, compared to net income of $2.6 million or $0.29 per diluted share for the first quarter of 2014 and $1.2 million or $0.13 per diluted share for the fourth quarter of 2014.

Investors Alert: Anheuser-Busch InBev SA/NV (NYSE:BUD), Twitter Inc (NYSE:TWTR), Cynosure (NASDAQ:CYNO), Celldex Therapeutics (NASDAQ:CLDX), Aerie Pharmaceuticals (NASDAQ:AERI)

On Tuesday shares of Anheuser-Busch InBev SA/NV (NYSE:BUD) closed at $117.20. Company’s sales growth for last 5 years was 5.10% and EPS growth for next 5 years is recorded as 6.70%. Anheuser-Busch InBev SA/NV (NYSE:BUD), increased profit by slightly more than expected as it made up for lower beer volumes with price hikes and higher-priced beers. First-quarter core profit (EBITDA) rose by 11.1 percent on a like-for-like basis to $3.97 billion. That compared with the $3.93 billion average forecast in a Reuters poll of analysts.

Twitter Inc (NYSE:TWTR) in last trading activity fell -1.21% to close at $37.42. Company weekly performance is -11.47% while its quarterly performance stands at -5.96%. Twitter Inc (NYSE:TWTR) is -33.17% away from its 52 week high. The Chief Financial Officer of Twitter Inc. (NYSE:TWTR), Anthony Noto, is now in charge of marketing at the social-media company, according to reports citing people familiar with the matter.

Cynosure, Inc. (NASDAQ:CYNO) in last trading activity moved up 6.55% to close at $36.27. Company weekly performance is 4.95% while its quarterly performance stands at 20.50%. Cynosure, Inc. (NASDAQ:CYNO) is 3.01% away from its 52 week high. Cynosure, Inc. (NASDAQ:CYNO), reported financial results for the three months ended March 31, 2015. Revenue was $74.9 million, an increase of 21 percent from the prior-year period. Product revenue in North America grew 45 percent to $31.3 million. Operating income was $2.1 million, up 53 percent year-over-year. On a non-GAAP basis, excluding acquisition costs and amortization of intangibles, income from operations was $5.1 million, up 4 percent from the first quarter of 2014.

On last trading day Celldex Therapeutics, Inc. (NASDAQ:CLDX) decreased -3.40% to close at $24.31. Its volatility for the week is 6.16% while volatility for the month is 6.27%. CLDX’s sales growth for past 5 years was -25.00% and its EPS growth for past 5 years was 6.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) monthly performance is -7.87%. On April 29, Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2015. Cash, cash equivalents and marketable securities as of March 31, 2015 were $359.8 million compared to $201.0 million as of December 31, 2014. Total revenue was $0.5 million in the first quarter of 2015 compared to $0.4 million for the comparable period in 2014.

On last trading day Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) decreased -2.84% to close at $10.61. Its volatility for the week is 10.99% while volatility for the month is 8.31%. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) monthly performance is -65.95%. On April 29, Robbins Geller Rudman & Dowd LLP announced that a class action has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) publicly traded securities during the period between August 6, 2014 and April 23, 2015 (the “Class Period”).

Moving Stocks: Aspen Technology (NASDAQ:AZPN), Celldex Therapeutics (NASDAQ:CLDX), American Caresource Holdings (NASDAQ:ANCI), SL Green Realty Corp. (NYSE:SLG), Citigroup (NYSE:C)

On Wednesday shares of Aspen Technology, Inc. (NASDAQ:AZPN) closed at $44.17. Company’s sales growth for last 5 years was 4.70% and EPS growth for next 5 years is recorded as 13.00%. Aspen Technology, Inc. (NASDAQ: AZPN) announced the retirement of Mark Sullivan, the company’s Executive Vice President and Chief Financial Officer, effective September 30, 2015.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) in last trading activity increased 2.59% to close at $24.54. Company weekly performance is -15.23% while its quarterly performance stands at 10.19%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is -25.23% away from its 52 week high. Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2015. Total revenue was $0.5 million in the first quarter of 2015 compared to $0.4 million for the comparable period in 2014.

On last trading day American Caresource Holdings, Inc. (NASDAQ:ANCI) decreased -5.37% to close at $2.29. Its volatility for the week is 10.70% while volatility for the month is 6.09%. ANCI’s sales growth for past 5 years was -16.90% and its EPS growth for past 5 years was -38.60%. American Caresource Holdings, Inc. (NASDAQ:ANCI) monthly performance is -17.92%. On 27 April, director at American Caresource Holdings, Inc. (NASDAQ:ANCI), Matthew Kinley exercised options of American Caresource Holdings for $8,715. The options were about to expired and Matthew Kinley kept the stocks.

SL Green Realty Corp. (NYSE:SLG) has 0.30% insider ownership. In last trading activity company’s stock closed at $124.06. It was reported on 22 April, that SL Green Realty Corp. (NYSE:SLG) and Prologis Inc. were nearly tied with just over $142 million each, SLG raising just $500,000 more in ATM offerings during Q4 than did PLD. Completing the top five was Sabra Health Care REIT, which raised $123.5 million during Q4.

On Wednesday shares of Citigroup Inc. (NYSE:C) closed at $53.76. Company’s sales growth for last 5 years was 5.20% and EPS growth for next 5 years is recorded as 25.69%. The Board of Directors of Citigroup Inc. (NYSE:C) declared a quarterly dividend on Citigroup’s common stock of $0.05 per share, payable on May 22, 2015 to stockholders of record on May 11, 2015.

Today’s Hot List: Agenus Inc. (NASDAQ:AGEN), Celldex Therapeutics (NASDAQ:CLDX), Mitcham Industries Inc. (NASDAQ:MIND), Wintrust Financial Corporation (NASDAQ:WTFC), IMRIS (NASDAQ:IMRS)

On Tuesday shares of Agenus Inc. (NASDAQ:AGEN) closed at $6.93. Company’s sales growth for last 5 years was 16.20%. Agenus Inc. (NASDAQ:AGEN), announced that primary and secondary endpoint data from GlaxoSmithKline’s (LSE/NYSE: GSK) randomized Phase 3 trial of HZ/su, a vaccine candidate for the prevention of shingles, was simultaneously presented at the 25th Scientific Conference of the European Society of Clinical Microbiology and Infectious Disease (ECCMID) in Copenhagen, and published in the New England Journal of Medicine. GSK’s HZ/su incorporates Agenus’ QS-21 Stimulon® adjuvant, which is designed to increase immune response to antigens.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) in last trading activity decreased -5.57% to close at $23.92. Company weekly performance is -14.17% while its quarterly performance stands at 0.89%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is -27.12% away from its 52 week high. On April 20, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced preclinical results that further support varlilumab’s expansion into combination studies with PD-1 inhibitors. The data were presented in a poster session entitled “Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site” at the 2015 American Association for Cancer Research Annual Meeting.

On last trading day Mitcham Industries Inc. (NASDAQ:MIND) moved up 0.81% to close at $4.96. Its volatility for the week is 3.78% while volatility for the month is 6.24%. MIND’s sales growth for past 5 years was 8.50% and its EPS growth for past 5 years was 28.28%. Mitcham Industries Inc. (NASDAQ:MIND) monthly performance is 0.81%.

Wintrust Financial Corporation (NASDAQ:WTFC) has 1.50% insider ownership while its institutional ownership stands at 94.50%. In last trading activity company’s stock closed at $49.27. On April 23, Wintrust Financial Corporation (NASDAQ:WTFC) announced that the Company’s Board of Directors approved a quarterly cash dividend of $0.11 per share of outstanding common stock. The dividend is payable on May 21, 2015 to shareholders of record as of May 7, 2015.

On last trading day IMRIS, Inc. (NASDAQ:IMRS) moved up 7.68% to close at $0.71. Its volatility for the week is 14.49% while volatility for the month is 8.75%. IMRIS, Inc. (NASDAQ:IMRS) monthly performance is -31.90%. On April 22, IMRIS, Inc. (NASDAQ:IMRS) announced that the Company received a letter, dated April 20, 2015, from the NASDAQ Stock Market LLC (“Nasdaq”) stating that for the previous 30 consecutive business days the bid price of the Company’s common stock closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5450(a)(1).

Morning Buzz: NeuroDerm (NASDAQ:NDRM), Celldex Therapeutics (NASDAQ:CLDX), Koninklijke Philips N.V (NYSE:PHG), Sanofi SA (ADR) (NYSE:SNY), FedEx Corporation (NYSE:FDX)

On Monday shares of NeuroDerm Ltd. (NASDAQ:NDRM) closed at $12.51. Jefferies Group assumed coverage on shares of Neuroderm (NASDAQ:NDRM) in a research note issued to investors on Thursday. The firm issued a buy rating and a $21.00 price target on the stock.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) in last trading activity moved down -15.85% to close at $25.33. Company weekly performance is -9.83% while its quarterly performance stands at 8.99%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is -22.82% away from its 52 week high. On April 20, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced preclinical results that further support varlilumab’s expansion into combination studies with PD-1 inhibitors. The data were presented in a poster session entitled “Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site” at the 2015 American Association for Cancer Research Annual Meeting.

On last trading day Koninklijke Philips N.V (NYSE:PHG) moved up 1.38% to close at $30.08. Its volatility for the week is 1.18% while volatility for the month is 1.11%. PHG’s sales growth for past 5 years was 1.30% and its EPS growth for past 5 years was -13.30%. Koninklijke Philips N.V (NYSE:PHG) monthly performance is 5.99%. Dutch consumer electronics company Koninklijke Philips NV (NYSE:PHG) reported Tuesday that its net income for the first quarter slid to 100 million euros from 137 million euros last year, mainly due to higher restructuring and acquisition-related charges and other items. Earnings per share declined to 0.11 euros from 0.15 euros.

Sanofi SA (ADR) (NYSE:SNY) has its institutional ownership stands at 9.50%. In last trading activity company’s stock closed at $52.28. French drugmaker Sanofi SA (ADR) (NYSE:SNY) said on Tuesday that the U.S. Food and Drug Administration has agreed to speed up the review of its drug application for a new Fabry disease treatment.

On last trading day FedEx Corporation (NYSE:FDX) moved down -0.54% to close at $169.03. Its volatility for the week is 0.99% while volatility for the month is 1.15%. FDX’s sales growth for past 5 years was 5.10% and its EPS growth for past 5 years was 85.20%. FedEx Corporation (NYSE:FDX) monthly performance is 2.14%. On April 21, FedEx announced that In Blue Handmade—a boutique maker of handmade leather products—is the grand prize winner of its third annual FedEx Small Business Grant Contest. Based in Asheville, North Carolina, In Blue will receive a $25,000 grant to invest in new tools and upgrade its studio, allowing the small team to fulfill larger contracts and meet growing demand.

Morning Buzz: Celldex Therapeutics (NASDAQ:CLDX), The Coca-Cola Company (NYSE:KO), BCE Inc. (NYSE:BCE), Penn Virginia Corporation (NYSE:PVA)

On Thursday shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) closed at $27.75. Company’s sales growth for last 5 years was -25.00% . On 6 April, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB).

The Coca-Cola Company (NYSE:KO) shares advanced 0.50% in last trading session and ended the day at $40.60. KO Gross Margin is 61.10% and its return on assets is 7.60%. The Coca-Cola Company (NYSE:KO) quarterly performance is -3.81%. The Coca-Cola Company (NYSE:KO) announced that Sandy Douglas, Senior Vice President and President of Coca-Cola North America, will present at 10:45 a.m. EDT, Tuesday, May 12, 2015 during the Goldman Sachs Global Staples Forum being held in New York City.

On last trading day BCE Inc. (NYSE:BCE) fell -0.38% to close at $44.30. Its volatility for the week is 1.05% while volatility for the month is 1.33%. BCE’s sales growth for past 5 years was 3.50% and its EPS growth for past 5 years was 8.80%. BCE Inc. (NYSE:BCE) monthly performance is 5.18%. Scotiabank upgraded shares of BCE Inc. (NYSE:BCE) from a sector perform rating to an outperform rating in a report issued on Monday. They currently have $60.00 target price on the stock, up from their previous target price of $58.00.

Penn Virginia Corporation (NYSE:PVA) has 0.30% insider ownership while its institutional ownership stands at 98.30%. In last trading activity company’s stock closed at $7.43. Penn Virginia Corporation (NYSE:PVA) announced that it will release its first quarter 2015 results after the market closes on Monday, May 11, 2015, and hold a conference call / webcast on Tuesday, May 12, 2015, at 10:00 a.m. ET.

Stocks in Focus: Celldex Therapeutics (NASDAQ:CLDX), Google Inc (NASDAQ:GOOG), Ford Motor Company (NYSE:F), Rosetta Genomics, (NASDAQ:ROSG), Fifth Street Finance (NASDAQ:FSC)

On Wednesday shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) closed at $28.07. Company’s sales growth for last 5 years was -25.00%. On April 6, Celldex Therapeutics, Inc. (NASDAQ:CLDX) declared that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB).

Google Inc (NASDAQ:GOOG) has 0.19% insider ownership while its institutional ownership stands at 31.90%. In last trading activity company’s stock closed at $532.53. The European Union accused Google Inc (NASDAQ:GOOG) on Wednesday (April 15) of cheating competitors by distorting Internet search results to favour its shopping service, and launched another antitrust investigation into its Android mobile operating system.

On last trading day Ford Motor Company (NYSE:F) advanced 0.63% to close at $16.07. Its volatility for the week is 0.93% while volatility for the month is 1.32%. F’s sales growth for past 5 years was 4.40% and its EPS growth for past 5 years was -1.40%. Ford Motor Company (NYSE:F) monthly performance is -2.55%. Ford Motor Company (NYSE:F) is expected to announce this week a $2.5 billion investment in Mexico, according to media reports.

Rosetta Genomics, Ltd. (NASDAQ:ROSG) has institutional ownership stands at 3.50%. In last trading activity company’s stock closed at $3.70. Rosetta Genomics Ltd. (NASDAQ:ROSG) announced on Tuesday that it has completed the acquisition of a molecular diagnostics and services company that serves doctors and reference laboratories nationwide.

On last trading day Fifth Street Finance Corp. (NASDAQ:FSC) increased 0.14% to close at $7.11. Its volatility for the week is 1.37% while volatility for the month is 1.52%. FSC’s sales growth for past 5 years was 42.60% and its EPS growth for past 5 years was 25.90%. Fifth Street Finance Corp. (NASDAQ:FSC) monthly performance is 3.19%.Standard & Poor’s Ratings Services on 2 April, said it revised its outlook on Fifth Street Finance Corp. (NYSE: FSC) to stable from positive. At the same time, we affirmed our ‘BBB-‘ issuer credit and issue-level ratings on the company. “We revised our outlook on FSC to reflect the company’s weakening operating performance and elevated leverage over the past several quarters that lowered our expectations for the company’s ability to improve its capital, leverage, and earnings [CLE] metrics,” said Standard & Poor’s credit analyst Olga Roman.

Traders Are Watching: Exxon Mobil Corporation (NYSE:XOM), Celldex Therapeutics (NASDAQ:CLDX), Primoris Services Corporation (NASDAQ:PRIM), Medtronic plc (NYSE:MDT), Pembina Pipeline Corporation (NYSE:PBA)

On Wednesday shares of Exxon Mobil Corporation (NYSE:XOM) closed at $84.06. Company’s sales growth for last 5 years was 5.50% and EPS growth for next 5 years is recorded as -1.15%. On 1 April, Exxon Mobil Corporation (NYSE:XOM) said that, it is reportedly contemplating a multibillion dollar expansion project at its Beaumont oil refinery in Texas.

On Wednesday shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) closed at $27.55. Company’s sales growth for last 5 years was -25.00%. On 6 April, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB).

On last trading day Primoris Services Corporation (NASDAQ:PRIM) moved down -3.73% to close at $18.58. Its volatility for the week is 4.13% while volatility for the month is 3.01%. PRIM’s sales growth for past 5 years was 34.90% and its EPS growth for past 5 years was 7.20%. Primoris Services Corporation (NASDAQ:PRIM) monthly performance is 8.02%. On 7 April, Primoris Services Corporation (NASDAQ:PRIM) announced a new Master Service Agreement (“MSA”) with a major utility customer with a three-year anticipated value of $36 million. The contract was secured by Q3 Contracting (“Q3C”), part of the West Construction Services segment.

Medtronic plc (NYSE:MDT) has 0.10% insider ownership while its institutional ownership stands at 69.80%. In last trading activity company’s stock closed at $76.39. On 7 April, Medtronic plc (NYSE:MDT) purchased Dutch diabetes clinic and research center – Diabeter. This reflects the company’s attempts to expand its presence in integrated health solutions, in line with its economic value strategy of becoming a leader in value-based healthcare. This acquisition marks Medtronic’s foray into a diabetes integrated care model approach.

On last trading day Pembina Pipeline Corporation (NYSE:PBA) moved down -2.00% to close at $32.37. Its volatility for the week is 2.53% while volatility for the month is 2.44%. PBA’s EPS growth for past 5 years was -1.01%. Pembina Pipeline Corporation (NYSE:PBA) monthly performance is 2.31%. On 31 March, Pembina Pipeline Corporation (NYSE:PBA) announced that it has entered into an agreement with a syndicate of underwriters co-led by Scotiabank and RBC Capital Markets (together, the “Underwriters”) pursuant to which the Underwriters have agreed to purchase from Pembina 8,000,000 cumulative redeemable rate reset class A preferred shares, Series 9 (the “Series 9 Preferred Shares”) at a price of $25.00 per share for distribution to the public.

Today’s Watch List: iDreamSky Technology Limited (NASDAQ:DSKY), Tesla Motors Inc (NASDAQ:TSLA), Celldex Therapeutics (NASDAQ:CLDX), First Bancorp (NASDAQ:FBNC), Sysco Corporation (NYSE:SYY)

On Wednesday shares of iDreamSky Technology Limited (NASDAQ:DSKY) closed at $8.65.
Stock analysts at Rosenblatt Securities assumed coverage on shares of iDreamSky Technology Limited (NASDAQ:DSKY) in a report issued on Thursday. The firm set a “buy” rating and a $11.00 price target on the stock. Rosenblatt Securities’ price objective would indicate a potential upside of 59.88% from the stock’s previous close.

Tesla Motors Inc (NASDAQ:TSLA) in last trading activity increased 2.17% to close at $207.67. Company weekly performance is 10.01% while its quarterly performance stands at -1.71%. Tesla Motors Inc (NASDAQ:TSLA) is -28.74% away from its 52 week high. Tesla Motors Inc (NASDAQ:TSLA) said that, it will unveil a new product on April 30 that isn’t a car, but is likely a stationary battery storage system.

On Wednesday shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) closed at $27.55. Company’s sales growth for last 5 years was -25.00%. On 6 April, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB).

First Bancorp (NASDAQ:FBNC) has 8.78% insider ownership while its institutional ownership stands at 50.80%. In last trading activity company’s stock closed at $17.47. First Bancorp (NASDAQ:FBNC) has declared a cash dividend on its common stock of $0.08 per share payable April 24, 2015 to shareholders of record as of March 31, 2015. The $0.08 per share dividend rate is the same as the rate declared in the comparable period of 2014.

On last trading day Sysco Corporation (NYSE:SYY) increased 0.47% to close at $38.15. Its volatility for the week is 1.13% while volatility for the month is 1.06%. SYY’s sales growth for past 5 years was 4.80% and its EPS growth for past 5 years was -2.20%. Sysco Corporation (NYSE:SYY) monthly performance is -1.24%. Sysco Corporation (NYSE:SYY) said that Joel Grade will take over as chief financial office on Sept. 1, replacing Chris Kreidler, who is leaving the position after six years.